Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy

• DOI: 10.2967/jnumed.108.060236
• Publication Date: 2009-07-18T08:43:10Z
• Authors: Daniel Putzer; Michael Gabriel; Benjamin Henninger; Dorota Kendler; Christian Uprimny; Georg Dobrozemsky; Clemens Decristoforo; Reto Josef Bale; Werner Jaschke; Irene Johanna Vir...
• Keywords: Bone scintigraphy

Somatostatin receptor scintigraphy is an accurate imaging modality for the diagnosis of neuroendocrine tumor. Because detection distant metastases has a major impact on treatment, early metastatic spread great importance. So far, no standard procedure become established bone from We compared diagnostic value CT with that novel somatostatin analog ⁶⁸Ga-1,4,7,10-tetraazacyclododecane-<i>N,N′,N″,N′′′</i>-tetraacetic acid-d-Phe¹-Tyr³-octreotide (⁶⁸Ga-DOTATOC) in such metastases. <b>Methods:</b> Fifty-one patients (22 women and 29 men; age range, 32–87 y) histologically verified tumor were included this study. PET scans fused using vacuum fixation device. ¹⁸F-NaF or ^99mTc-dicarboxypropane diphosphonate clinical follow-up served as reference standard. <b>Results:</b> Twelve 51 had evidence any available modalities, 37 ⁶⁸Ga-DOTATOC results true-positive true-negative 12 patients, false-positive one, false-negative another, resulting sensitivity 97% specificity 92%. detected at significantly higher rate than did (<i>P</i> &lt; 0.001). Furthermore, conventional confirmed but not reveal additional tumors patients. <b>Conclusion:</b>⁶⁸Ga-DOTATOC reliable, method Our show are less primary staging restaging